

Current and future targets for faecal microbiota transplantation

McIlroy, James; Segal, Jonathan P; Mullish, Benjamin H; Nabil Quraishi, Mohammed; Gasbarrini, Antonio; Cammarota, Giovanni; Ianaro, Gianluca

DOI:

[10.1016/j.humic.2018.08.004](https://doi.org/10.1016/j.humic.2018.08.004)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

McIlroy, J, Segal, JP, Mullish, BH, Nabil Quraishi, M, Gasbarrini, A, Cammarota, G & Ianaro, G 2018, 'Current and future targets for faecal microbiota transplantation', *Human Microbiome Journal*.
<https://doi.org/10.1016/j.humic.2018.08.004>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Current and future targets for faecal microbiota transplantation

James Mcilroy, Jonathan P Segal, Benjamin H Mullish, Mohammed Nabil Quraishi, Antonio Gasbarrini, Giovanni Cammarota, Gianluca Ianiro

PII: S2452-2317(18)30022-8
DOI: <https://doi.org/10.1016/j.humic.2018.08.004>
Reference: HUMIC 45

To appear in: *Human Microbiome Journal*

Received Date: 26 May 2018
Revised Date: 13 July 2018
Accepted Date: 21 August 2018

Please cite this article as: J. Mcilroy, J.P. Segal, B.H. Mullish, M. Nabil Quraishi, A. Gasbarrini, G. Cammarota, G. Ianiro, Current and future targets for faecal microbiota transplantation, *Human Microbiome Journal* (2018), doi: <https://doi.org/10.1016/j.humic.2018.08.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Invited review article – Human Microbiome Journal**

2 **Title**

3 Current and future targets for faecal microbiota transplantation

4 **Authors**

5 James Mcilroy*^{1,2}, Jonathan P Segal*^{3,4}, Benjamin H Mullish⁴, Mohammed Nabil Quraishi⁵, Antonio Gasbarrini⁶, Giovanni
6 Cammarota⁶, Gianluca Ianaro⁶

7
8 *** Denotes joint first author**

9 **Affiliations**

- 10 1. School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, AB25 2ZD
11
12 2. EnteroBiotix Limited, Aberdeen Blood Transfusion Centre, Foresterhill Road, Foresterhill, Aberdeen, AB25 2ZW
13
14 3. IBD Unit, St Mark's Hospital, Harrow, UK
15
16 4. Department of Surgery and Cancer, Imperial College, London, United Kingdom
17
18 5. Institute of Immunology and Immunotherapy, University of Birmingham, Department of Gastroenterology, University Hospital,
19 Birmingham, United Kingdom
20
21 6. Internal Medicine, Gastroenterology and Liver Unit, Gastroenterology Area, Fondazione Policlinico Gemelli, Università
22 Cattolica del Sacro Cuore, Rome, Italy
23
24

25 **Correspondence**

26 Dr. Gianluca Ianiro; Internal Medicine, Gastroenterology and Liver Unit, Gastroenterology Area, Fondazione Policlinico Universitario
27 Gemelli, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 – Rome, Italy. Tel/fax numbers: +39 06 30156265; e-mail
28 address: gianluca.ianiro@hotmail.it

29 **Key words:**

30 Faecal microbiota transplantation, FMT, microbiota, microbiome, bacteriotherapy

31 **Figures:** 2

32 **Tables:** 3

33 **Competing Interests:**

34 JM has received salary, consultancy fees and other from EnteroBiotix Limited and Biotechspert Limited during the conduct of the
35 study

36 **Authorship**

37
38 All authors have made substantial contributions to the conception and design of the study, the acquisition of data, the analysis and
39 interpretation of data. All authors have contributed to drafting the article and revising it critically for important intellectual content. All
40 authors approved the final approval of the version to be submitted.

41
42 Words: 4315 (max 3000)

43 Abstract: 222

44 References:85 (max 50)

45

46 **Abstract:**

47

48 The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria,
49 viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been
50 restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation
51 sequencing techniques has enhanced our understanding of its structure, diversity and function.

52

53 There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and
54 function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in
55 an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical
56 and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in
57 interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent *Clostridium difficile*
58 infection.

59

60 Despite success in treating recurrent *Clostridium difficile*, there remain many unknowns about how best to optimise its preparation,
61 regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding
62 faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation
63 of faecal microbiota transplantation.

64

65

66 1 Introduction

67

68 The human gastrointestinal tract is home the most dense, rich and diverse microbial ecosystem in the human body. The highest
69 concentration of microbes live within the colon, where there are an estimated 10^{12} cells per gram of intestine luminal contents (1).
70 These microbial communities, the habitat they live in, and their spectrum of activity are collectively known as the gut microbiome. In
71 this review, the term 'microbiota' will be used when reference is made to only the microorganisms themselves and the term
72 'microbiome' will be used when referring to the microbial communities, their genetic potential and the environment that they occupy.

73

74 The gut microbiome is composed of archaea, bacteria, viruses and eukarya (2). The vast majority of research into the gut microbiome
75 that has been conducted to date has focussed on the structure and function of the bacterial communities. By contrast, there has been
76 relatively sparse research conducted on the viruses and bacteriophages (virome) (3), fungi (mycome) (4,5) and other micro-
77 eukaryotes such as protozoa (6). For the purposes of this review, the term 'gut microbiota' will refer to the bacterial communities that
78 reside inside the intestinal tract, unless stated otherwise.

79

80 Until relatively recently, the majority of knowledge relating to the gut microbiota has been acquired through culture-based techniques,
81 which are labour-intensive and not high-throughput. Furthermore, they require specific conditions to optimise bacterial growth (e.g.
82 an anaerobic environment) which inevitably means that much of the gut microbiota is missed. The invention and subsequent
83 implementation of next-generation sequencing technologies have provided researchers with the apparatus and capabilities to analyse
84 the gut microbiota without the need to culture microbes (7). Several international studies and initiatives, including large-scale
85 endeavours such as the Human Microbiome Project and MetaHit, have used these tools to identify over 1000 species within the gut,
86 mainly belonging to four major phyla, namely: *Actinobacteria*, *Proteobacteria*, *Firmicutes*, and *Bacteroides* (2)(8). These large cohort

87 studies also showed that relative abundance of these phyla differs between individuals (9). However, the clinical and biological
88 significance of these observations is currently poorly understood.

89

90 Microbial sequencing enables us to know which microbiota community members are present but are unable to elicit their specific
91 role. In view of this, numerous experiments have been undertaken to better understand the function of the gut microbiota (10,11).
92 These experiments have shown that the bacterial communities underpin several important physiological functions such as nutrient
93 absorption, bile and short chain fatty acid metabolism, activity of the immune system, vitamin production and protection from
94 xenobiotics (12). The functions of the gut microbiota appear to be ubiquitous across the healthy population (9). In contrast, the
95 structure and composition of the gut microbiota appears to differ between people. The significance of differences in structure and
96 composition of the microbiota between person to person is currently unclear. However, it is known that a sensitive and complicated
97 symbiosis exists between humans and their microbial inhabitants. Disturbances to this symbiotic relationship is known to have
98 deleterious effects on the host. For example, in the case of *Clostridioides* (formerly *Clostridium*) *difficile* infection (CDI), the use of
99 broad-spectrum anti-microbial agents disrupts normal microbial diversity and function. This in turn, allows germination, colonisation
100 and toxin production by *C. difficile*, resulting in clinical symptoms of diarrhoea often associated with blood, pain and significant
101 morbidity and mortality if left untreated. Therapeutic modalities focussed on restoring gut microbiota diversity and function are
102 emerging and represent a promising therapeutic strategy. For example, a medical treatment called Faecal Microbiota Transplantation
103 (FMT), has shown efficacy in randomised controlled trials for treatment of recurrent CDI (13).

104

105 This review provides an update on current understanding of FMT for CDI and gives an insight into best practice for all aspects of the
106 treatment. The evidence for FMT in indications beyond CDI is also discussed.

107

108 **2** *Clostridioides difficile* infection (CDI)

109

110 *Clostridioides difficile*, is an anaerobic, spore-forming, toxin producing bacterium that colonises the intestinal tract of around 2-5% of
111 the healthy population (14). It was first isolated by Hall & O'Toole in 1935 from the gut of a healthy newborn baby (15). However, its
112 implication as a human pathogen was not known until 1978, when George and colleagues discovered that *Clostridioides difficile* was
113 heavily implicated in many cases of antibiotic-associated diarrhoea. These days, it is known as the causative pathobiont in most
114 cases of post-antibiotic infectious diarrhoea (12). In 2011, there were approximately 500,00 cases of CDI, resulting in 29,000 deaths
115 in the USA (16). The European Centre for Disease Prevention and Control estimated using a point-prevalence survey that ~124,000
116 patients developed health-care-associated CDI within the European Union annually.

117

118 A detailed description of the pathogenesis of CDI is beyond the scope of this review. The major risk factor for the development of
119 CDI is the use of broad-spectrum antimicrobial agents (17), which has led many to hypothesise that in health, the indigenous gut
120 microbiota functions to prevent the germination and overgrowth of *C. difficile* (as well as other enteropathogens), a concept known
121 as 'colonisation resistance'. Potential mechanisms driving this phenomenon include the production of bacteriocins and phage by
122 the indigenous communities, and alterations of gut microbiota-host metabolism interactions - which may impact competition for
123 nutrients and physical space (18,19). As one example of interest, restoration of gut microbiota-mediated bile acid metabolism has
124 been demonstrated after successful FMT for rCDI(20). Particular bile acids have been demonstrated *in vitro* to have profound
125 effects on different parts of the *C. difficile* life cycle, with the primary bile acid taurocholic acid being a major progerminant, and
126 secondary bile acids (e.g. deoxycholic acid) inhibiting *C. difficile*'s vegetative growth(21). As such, the degradation of taurocholic
127 acid and enrichment of gut secondary bile acids that accompanies FMT for rCDI(20) may be an important mechanistic explanation
128 for FMT's success.

129

130 There are a broad range of clinical manifestations of CDI, ranging from mild diarrhoea to life-threatening toxic megacolon (22). First
131 line treatment for CDI involves stopping the inciting antibiotic and rehydrating the patient. Following this, the recommended treatment
132 is a course of antibiotics. Those currently licensed in the EU are: metronidazole, vancomycin and fidaxomicin. Initial treatment is
133 generally successful (23), however, the risk of recurrence within eight weeks is 15-25%, which rises to 40-65% in patients that have
134 had more than a single recurrence (24). In patients with multiple relapses, the treatment options include: a pulsed/ tapered course of
135 vancomycin or fidaxomicin, a novel anti-toxin B monoclonal antibody called Bezlotuzumab (25,26), and faecal microbiota
136 transplantation (FMT). Despite these treatment options, there has been the emergence of hypervirulent strains of CDI, including
137 027, which are less responsive to antimicrobial treatments and therefore drive the need for alternative treatment options (27).

138

139 3 Faecal microbiota transplantation (FMT): history and definitions

140

141 In the late 1950's, the Chief of Surgery at Denver General Hospital, Mr Ben Eiseman, decided that he would try to treat four of his
142 patients suffering from post-antibiotic diarrhoea by transferring stool from a healthy donor into their intestinal tracts with good results.
143 Since the pioneering work of Eiseman, a large body of controlled and non-controlled evidence has accumulated showing that FMT is
144 a highly effective therapeutic strategy in patients suffering from recurrent CDI (28). A detailed analysis of the literature is presented
145 in further detail in a later section of this review.

146

147 A recent systematic review published by Quraishi and colleagues reported that across seven randomised trials and 30 case series,
148 FMT was more effective than vancomycin in resolving recurrent and refractory CDI, with clinical resolution across all studies being
149 95% (28). In contrast, the efficacy of vancomycin in patients with recurrent CDI not responsive to multiple courses of antibiotics is

150 known to be around 30% (24). In addition to recurrent and refractory CDI, a recent study reported that FMT also improves survival in
151 patients suffering from severe CDI(29).

152

153 The majority of FMT reported in the literature is allogenic in nature (Figure 1) and involves the transfer of faecal microbiota from a
154 healthy donor into the intestinal tract of a recipient. However, it should be noted that FMT can also be autologous in nature (Figure
155 2), where faecal microbiota is banked by a person and reinstated at a later date, potentially after medical treatment that alters the
156 structure and/or function of the gut microbiome. A variety of methods can be utilised to deliver the faecal microbiota as part of the
157 procedure, such as nasoduodenal tube, nasogastric tube, rectal enema and the biopsy channel of a colonoscope (14). Recently,
158 there has been interest in delivering the faecal microbiota through enteric coated capsules (30,31). Enteric coated capsules aid the
159 design of placebo controlled studies and remove the need for the invasive medical procedures currently used to administer the faecal
160 microbiota. However, in the studies, patients were asked to swallow 30-40 capsules, which could potentially pose problems for certain
161 groups of patients in particular, e.g. with swallowing disorders. In light of this, the optimal delivery method remains unclear and future
162 research should determine if the capsule burden can be decreased (32).

163

164

165

166

167


168

169

170

171

172 **Figure 1:** A schematic overview of allogenic and autologous Faecal Microbiota Transplantation using banked frozen faecal
 173 microbiota.
 174



175

176

177 4 Current regulatory landscape

178

179 There is worldwide variation in the regulation of faecal microbiota for therapeutic application (33). In some countries, such as the UK
 180 (34), the USA (35) and France (36), faecal microbiota is regulated as a medicinal product. In others, such as Italy, it is regulated as
 181 a tissue and in others, such as the Netherlands, there are currently no regulatory guidelines (37). In the USA, despite announcing
 182 that faecal microbiota is regulated as a medicinal product, the FDA has opted to exercise enforcement discretion for FMT used for
 183 recurrent or fulminant CDI which fail to respond to standard therapy (38). In Europe, the EU commission provided a legal opinion on
 184 the regulation of FMT in December 2014. The commission considered that for the purposes of the EU Tissues and Cells Directive
 185 (EUTCD), faecal microbiota is a 'combined substance', meaning that it contain human cells and other components not from human

186 origin. There is a precedence for combined substances falling under the EUTCD. However, the commission concluded that for the
187 purposes of FMT, the cells are not the active component of this substance and therefore are not 'intended for human applications'
188 within the definition of the EUTC. In the future, it is possible that these policies and stances will evolve in time as the evidence base
189 for FMT matures and progresses.

190 5 FMT practicalities in clinical practice

191 192 5.1 Donor screening and selection

193
194 Historically, patients were encouraged to select their own donor from friends and family. However, evidence has emerged showing
195 that faecal microbiota obtained from unrelated 'universal donors' is equally efficacious (30). Furthermore, there is evidence from blood
196 transfusion medicine showing that recipient-selected donors are not less likely to test positive for infectious disease than unrelated
197 'universal' volunteer donors(39). These data, coupled with evidence showing that faecal microbiota can be frozen with a
198 cryoprotectant and banked for over six months at -80 degrees Celsius (40) without a loss of viability and efficacy (13) has prompted
199 many centres to set up donor programmes using pre-screened unrelated donors who are anonymous to the recipient. Frozen banking
200 also allows for stool to be quarantined, which has the added benefit of reducing the risk of infectious pathogens not being picked up
201 because of screening being performed during a seroconversion window. The concept of frozen banking is well established, however,
202 the duration of quarantine and the frequency of retesting is less well agreed.

203
204 Currently, there is no consistent evidence that links donor characteristics to any influence on patient outcomes. In light of this, donor
205 screening is focussed on risk reduction (41). Consensus guidance published by Cammarota et al (32) recommends that donors are
206 extensively screened by a medical questionnaire prior to undergoing blood and stool testing. The medical questionnaire is usually
207 designed to elicit information regarding risk factors for transmittable pathogens and conditions and diseases that could potentially be

208 microbiome-mediated (32). As a general rule, prospective donors with active infection or who disclose risk factors for infection should
 209 be excluded. Regarding microbiome-mediated conditions and diseases, as FMT involves the transfer of a largely uncharacterised
 210 active microbial suspension, there is a theoretical possibility that a propensity to diseases linked to the gut dwelling microbial
 211 communities could be transferred (6). Therefore, it is recommended that centres and doctors adopt microbiome-specific exclusion
 212 criteria, such as diagnosed metabolic disorders and obesity, a personal or family history of gastrointestinal disease and a family
 213 history of colorectal cancer (42).

214

215 There is relative uniformity different centres and countries (Table 1) with regards to blood screening protocols. By analogy, it may be
 216 best practice to try and match the serostatus of donors to patients for CMV and EBV which is likely to be an important consideration
 217 in immunocompromised recipients.

218

219 **Table 1:** A table outlining blood testing protocols in a number of commercial and non-commercial stool banks. These are presented
 220 alongside EU consensus guidance published by Cammarota et al (32).

	OpenBiome(43)	NDFB(37)	EnteroBiotix	EU Guidance(32)
Test				
CMV	-	X	X	X
EBV	-	X	X	X
Hepatitis A	X	X	X	X
Hepatitis B	X	X	X	X
Hepatitis C	X	X	X	X

Hepatitis E	X	X	X	X
HIV Type 1/2	X	X	X	X
HTLV	X	X	X	X
<i>Treponema</i>	X	X	X	X
<i>Strongyloides</i>	X	X	X	X

221

222 In contrast to the general uniformity and convergence observed in Table 1 between donor blood testing protocols, stool screening
 223 protocols vary between centres and countries (37). In general, clinical trials appear to adopt similar testing protocols to those outlined
 224 in the seminal randomised controlled trial published by Van Nood et al (13,44,45). Between stool banks, most of the variation between
 225 protocols is found between policies on screening for multi-drug resistant organisms, as well as contagious viruses such as Astrovirus
 226 and Sapiovirus (37). In the absence of robust data on optimal donor testing and management, centres should take a multi-disciplinary
 227 approach to developing screening protocols and processes. The current consensus guidance criteria for screening and subsequent
 228 selection will likely be updated to reflect improved understanding of transferring potential pathogens through FMT.

229

230 5.2 Recipients of FMT

231

232 FMT works for recurrent CDI, and probably also refractory CDI, although refractory is a term that is poorly-defined. Interestingly,
 233 recent data suggests that FMT may be a suitable alternative to antibiotic treatment in primary CDI (46) although numbers in the
 234 studies are small to make definitive conclusions and recommendations. There are many unknowns about who should and shouldn't
 235 receive FMT. Many studies involving FMT have excluded patients who are immunocompromised, pregnant, (47,48) as well as those
 236 with chronic diarrhoea(47–49), decompensated cirrhosis (48) and those with food allergies (48,50). Whilst there is little evidence that

237 these exclusions are associated with significant risk from FMT, it should be offered with caution in these patient groups and based
238 on theoretical risk avoided in those patients with anaphylactic food allergies.

239

240

241 5.3 Faecal processing and storage

242

243 The methods, techniques and processes for faecal collection and preparation prior to administration have not been standardised and
244 vary across the literature. Guiding principles have, however, been published in consensus papers.(32,51) Faecal material should be
245 collected from donors in a designated clean air tight collection container. Once the stool has been obtained, it is advisable to process
246 the sample within six hours (49) to preserve as much viability as is practically possible. European consensus guidance recommends
247 that >30g of faecal microbiota is used per FMT. However, we recommend that this is increased to >50g of in light of evidence showing
248 that that using <50g increases the risk of CDI recurrence (52). Once weighed out, stool is usually homogenised with an excipient so
249 that it can be infused as part of the FMT procedure. The most commonly used in the literature is physiological saline, however, other
250 excipients such as water (53) and milk (54) have been described previously. After homogenisation, the faecal microbiota is usually
251 filtered to remove large particulates. If the material is to be frozen, then glycerol or another cryoprotectant should be added to the
252 suspension to preserve the viability of the bacterial communities when the suspension is frozen. There is data showing that faecal
253 microbiota remains viable and efficacious for six months when frozen with glycerol (45).

254

255 5.4 FMT preparation and procedure

256

257 On the day of the procedure, frozen faecal microbiota preparations should be thawed overnight in a refrigerator or at room temperature
258 (55) for several hours. The Netherlands Donor Faeces Bank recommends 5 hours of thawing if at room temperature (37). Thawing
259 the preparation in a water bath is not recommended as there are published reports of water baths causing microbial entry during the
260 thawing process in blood transfusion medicine (56).

261

262 Patients undergoing FMT are typically asked to discontinue antibiotic therapy 1-3 days before the procedure. European consensus
263 guidance also recommends the use of bowel lavage the day before FMT. It has been suggested that this may reduce the abundance
264 of *C. difficile* and potentially remove any residual antimicrobial in the colon, and enhance engraftment of the donor faecal microbiota
265 (51) however these hypotheses have yet to be tested in a robust randomised controlled clinical trial.

266

267 Further patient preparation to be considered is the use of proton pump inhibitors (PPI) prior to upper GI FMT. This theoretically helps
268 to minimise acidity which may impair engraftment of transplanted microorganisms. Importantly, whilst some studies advocate the use
269 of PPI prior to receiving FMT via the upper GI route (57–63), there appears to be no difference in efficacy when PPI has not been
270 utilised. The use of a prokinetic for FMT via upper GI route has been described (64) and theoretically can reduce the risk of aspiration
271 when utilising this route. When considering lower GI administration loperamide and other anti-motility medications have been utilised
272 with the aims of prolonging FMT exposure to the gut and aid retention of the FMT(65–67). Whilst these additional patient preparation
273 points should be considered, there is limited evidence for their use.

274

275 As briefly outlined earlier in this review, there are several potential routes of administration for FMT. These are: (a) instillation of faecal
276 microbiota into the upper GI tract through nasogastric or nasoduodenal tube (13), (b) instillation into the colon by colonoscopy (44)
277 or flexible sigmoidoscopy(c) instillation into the colon/rectum through an enema(53) and finally (d) administration through orally-
278 delivered capsules (30). The optimal route of delivery remains unclear, with each having potential benefits and drawbacks. For
279 example, upper GI administration may require less sedation than colonoscopy but several studies have shown that colonic delivery
280 may provide a slight, but not statistically significant, efficacy benefit (28,58,68). In addition, there have been several documented
281 cases of aspiration pneumonia (59,69) as a result of upper GI delivery (see **Section 7**). Further RCT's are required in order to

282 establish the optimal route of administration. Clinicians seeking to administer FMT should approach each clinical situation where FMT
283 is potentially indicated on a case by case basis, taking the patients comorbidities and preferences into account.

284 6 Fresh Vs Frozen

285

286 Two randomised studies have evaluated the efficacy of fresh FMT versus frozen FMT. In one non-inferiority study, it was found that
287 that a frozen enema of FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of
288 recurrent or refractory CDI(55). The other study supported this finding, and suggested that remission rates for CDI were similar when
289 comparing fresh and frozen FMT delivered via colonoscopy ($n=25/25$ vs $20/24$ respectively, $p=0.233(65)$).

290

291 On a logistical level, frozen FMT is likely to be the preferred choice due to ease of transferring from centralised stool banks,
292 traceability, and from a regulatory perspective. Research has shown that stool banking is more cost effective than using directed
293 donors and fresh samples(70). Furthermore, research has demonstrated that frozen stool retains its viability and efficacy for six
294 months when stored in a -80°C freezer,(45,50,70) however decreasing viability of the gut microbiota has been shown beyond this
295 period.

296 7 Adverse events and unintended consequences

297

298 Those adverse events reportedly occurring around the time of administration of the faecal microbiota FMT tend to be related to the
299 procedure itself. Procedural adverse events described after colonoscopic administration include mild nausea and vomiting (attributed
300 to sedation for the colonoscopy), and minor mucosal tears during colonoscopy. A case of microperforation (71,72) following biopsy
301 of an area of possible small bowel ischaemia in a patient with chronically dilated small bowel has also been reported; the case was
302 subsequently successfully treated conservatively(66). One death due to witnessed aspiration at the time of colonoscopy has been

303 described (73). Two deaths related to aspiration pneumonitis that are likely attributable to upper GI administration of FMT have been
304 reported (73,74) along with several cases of regurgitation and vomiting (74). However, some of these patients were receiving a
305 considerably higher volume of FMT than is typically administered by the upper GI route (i.e. 500ml) (74). One of the fatal episodes
306 using higher volumes occurred in a patient with a swallowing disorder following oropharyngeal radiation after surgical removal of a
307 maxillary carcinoma. Many centres using smaller volumes of FMT for upper GI administration have not consistently noticed similar
308 problems.

309

310 In the hours to days following FMT, the most common adverse events are constitutional or gastrointestinal symptoms, including
311 diarrhoea, abdominal cramps/pain, belching, constipation and nausea (74). These are typically mild and self-limiting. Successful
312 treatment usually centres around conservative management. However, it should be noted that a recent meta-analysis described a
313 22.7% rate of worsening of IBD activity in patients with IBD that received FMT as treatment for rCDI (75) but the authors of this study
314 did note significant heterogeneity in the reviewed literature. Further studies are required to further delineate the relationship between
315 FMT and risk of IBD flare.

316

317 There are concerns about the risk of transmission of infection from donor to recipient through FMT. However, there are very few
318 reports of this in the literature. Two cases of Norovirus infection occurring soon after FMT have been reported, however, the authors
319 concluded that these infections were more likely to represent environmental transmission rather than direct donor-to-recipient transfer
320 (76).

321

322 Beyond what has been described above, there have been reported cases of autoimmune and inflammatory conditions developing
323 soon after FMT. These include: microscopic colitis, Sjögren's syndrome, follicular lymphoma, peripheral neuropathy, immune
324 thrombocytopenia and rheumatoid arthritis (77,78). It should be noted, however, that these observations have only been published

325 in case reports and have not been replicated in randomised controlled trials. A widely-publicised case study reported marked weight
326 gain in a patient being treated for recurrent CDI using an overweight family member as a donor(79). These results have not been
327 replicated elsewhere in the literature and therefore does not seem likely to be a true risk (80).

328

329 As faecal microbiota contains a largely uncharacterised consortia of microorganisms, there is a theoretical risk that FMT could transfer
330 a disease phenotype from the donor to the recipient. Long-term, prospective follow-up of recipients is required to fully assess this risk
331 and donor screening programmes should be designed to exclude donors that are most likely to harbour significant risk.

332 8 Efficacy in Non-CDI indications

333

334 The role of FMT has been explored in a multitude of indications beyond CDI. Most of the research that has been conducted has been
335 uncontrolled and there is significant heterogeneity between case reports and case series that report positive outcomes (81). There is
336 likely to be a significant degree of reporting bias and therefore the positive outcomes should be approached with caution. However,
337 there have been studies published in several indications beyond CDI, including: ulcerative colitis, metabolic syndrome, functional
338 bowel disorders, hepatic encephalopathy and multi-drug resistant organisms.

339

340 8.1 Ulcerative colitis

341

342 To date, there have been four RCTs (three published, one abstract) investigating clinical endpoints in UC following treatment with
343 FMT (44). Three of these four RCTs showed positive outcomes, with patients receiving donor FMT more likely to reach clinical
344 endpoints of response and remission compared to placebo or autologous FMT. However, these studies differed in methodology, with
345 variations in patient inclusion criteria, donor stool processing and preparation, administration and the faecal microbiota infusions. The
346 successful studies delivered the faecal microbiota through the lower GI route and used a more intense treatment protocol with up to

347 a total of 40 over 8 weeks. Interestingly, the RCT that prepared the faecal microbiota under anaerobic conditions resulted in the
348 highest clinical response and remission.

349

350 8.2 Functional bowel disorders

351

352 There have been two RCTs that have been published investigating the use of FMT as a treatment for functional bowel disorders.
353 These two studies report positive outcomes. A Norwegian study of 90 patients with diarrhoea-predominant irritable bowel syndrome
354 (IBS) demonstrated that a an improvement in IBS severity scores in those who received a single infusion of FMT compared to those
355 who received placebo(82). A second study showed marked improvement in spontaneous bowel movements in 60 patients with slow
356 transit constipation receiving six infusions of FMT when compared to conventional treatment (83).

357

358

359 8.3 Metabolic syndrome

360

361 To date, there have been two studies investigating the efficacy of FMT in patients with metabolic syndrome(84). Both of these studies
362 suggested that FMT from lean donors may improve peripheral insulin sensitivity in patients suffering from metabolic syndrome. In
363 both studies the effect size was deemed to be statistically significant. However, the effects were transient (with benefits found only at
364 six weeks – but no longer – post-FMT), which suggests that long-term repeated dosing may be required if FMT is to potentially be an
365 effective treatment option in metabolic syndrome.

366

367 8.4 Hepatic encephalopathy

368

369 In a study of 20 patients suffering from hepatic encephalopathy caused by liver cirrhosis, improvements in encephalopathy and a
370 reduction in cirrhotic complications were noted in the FMT arm, but not amongst patients receiving standard of care medical
371 therapy(85). However, as the patients in the FMT arm in this study also received antibiotics (rifaximin) and lactulose throughout, the
372 results should be interpreted with caution.

373

374 8.5 Decolonisation of multidrug resistant organisms

375

376 There is a growing interest that FMT may promote decolonisation of multidrug resistant organisms(86–88). As yet there are no
377 randomised controlled studies that explore this but it is gathering interest and may provide a novel therapeutic avenue to target
378 multidrug resistant organisms.

379 9 Conclusion and future perspectives

380

381 FMT is an effective treatment for recurrent CDI regardless of the route of delivery and method of preparation and storage. The use
382 of encapsulated and orally administered faecal microbiota will expand access for patients and simply the design of placebo controlled
383 trials. Short-term follow-up suggests that FMT appears to be a relatively safe treatment, with the majority of side effects being mild
384 and self-limiting. The long-term sequelae of FMT are currently not known and future work should focus on investigating this. There is
385 emerging evidence suggesting that FMT may have a treatment utility beyond recurrent CDI, although further RCT evidence is required
386 before wide scale adoption may occur for these indications. In the future, it is possible that FMT may ultimately be replaced by defined
387 consortia of bacteria or single strains that have been rationally-selected based on their mechanism of action. There are several
388 commercial and non-commercial organisations and groups working on this (89). However, it should be noted that faecal microbiota
389 is a highly complicated starting substance and those that wish to reverse engineer it will probably have to elucidate the ways in which
390 the microbial communities within the samples interact with each other, as well as unravelling its mechanism of action. In light of this,

391 it may be quite some time before an optimal combination of microbes is discovered and ultimately taken into the clinic. Until then,
392 doctors and researchers should focus on making FMT as safe and effective as possible by adhering to consensus guidance
393 recommendations and supporting interventional FMT studies.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434 **Supplementary materials**

435

436

437 **Table 1.** *A table outlining published Randomised trials of FMT in in C.diff infection*

438

Author	FMT comparison vs	Demographics			Donors	Route	Fresh/frozen (dose) comparator	Outcome
		N	M/F	Age				
Camacho-Ortiz <i>et al</i> , <i>PLoS ONE</i> , 2017	FMT arm	7	4/3	Mean of 46.7 (+/- 15.8) years.	>18years, non-pregnant, BMI 20-25kg/m ²	Upper 14 Lower 1	Frozen 45ml of pooled donor stool (from three donors), at ~0.19g/ml	71.4% (n=5/7)
	Vancomycin	9	6/3	Mean of 46.7 (+/- 15.8) years.	n/a	oral	250 mg every 6 hours for 10-14 days	88.9% (n=8/9)
Cammarota <i>et al</i> , <i>Alimentary Pharmacology and Therapeutics</i> , 2015	FMT	20	8/12	Mean 71 (range 29-89) years.	Less than 50 years of age, no antibiotics within past 6 months	All lower	Fresh- dose not specified	90% (n=18/20).
	Vancomycin (19	8/11	Mean 75 (range	n/a	Oral	125mg four times daily for 10 days, follow by a pulse regimen (125-	26% (n=5/19).

				49-93) years.			500mg/day every 2-3 days, for at least three weeks).	
<i>Allegretti et al, Gastroenterology (abstract), 2016</i>	FMT capsules (30 pills once).	10	Not stated	Not stated	Donors were unrelated donors from universal stool bank (OpenBiome	Oral	Frozen-30 pills once	70% (n=7/10).
	FMT capsules 30 pills daily on two consecutive days	9	Not stated	Not stated	Donors were unrelated donors from universal stool bank (OpenBiome	oral	Frozen-30 pills daily on two consecutive days	77.8% (n=7/9).
<i>Hota et al, Clinical Infectious Diseases, 2016</i>	FMT	16	5/11	75.7 +/- 14.5 years.	Not stated	lower	Fresh -50g	43.8% (n=7/16).
	Vancomycin	12	4/8	Mean 69.6 +/- 14.2 years	Not stated	oral	vancomycin 125 mg orally every 12 hours for 1 week; then, vancomycin 125 mg orally every 24 hours for 1 week; then, vancomycin 125 mg orally every second day for 1 week; then, vancomycin 125 mg orally every third day for	58.3% (n=7/12).
<i>Jiang et al, Alimentary Pharmacology and Therapeutics, 2017</i>	FMT	25	4/21	Mean 75 (range 19-97) years	Not stated	Lower	Fresh and frozen-50g	Fresh 100% (n=25/25) Frozen 83% (n=20/24).

	Lyophilised FMT.25	24	6/18	Mean 62.5 (range 33-88) years.	Not stated	Lower	Frozen-50g	78% (n=20/23).
Kao <i>et al</i> , JAMA, 2017	FMT capsules	57	14/43	Mean 58.7 (+/- 18.5) years.	Unrelated	Oral	Frozen-80-100g	96.2% (n=51/53)
	Colonoscopic FMT	59	13/36	Mean 57.4 (+/- 19.1) years.	Unrelated	Colonoscopic	Frozen-80-100g	96.2% (n=50/52).
Kelly <i>et al</i> , Annals of Internal Medicine, 2016	Donor FMT	22	4/18	Mean age 48 (+/- 16) years	Not stated	Colonoscopic	Fresh Mean stool dose of 64 g (standard deviation of 25 g; range, 20 to 100g).	90.9% (n=20/22).
	Autologous FMT	24	5/19	Mean age 55 (+/- 14) years.	Not Stated	Colonoscopic	Fresh Mean stool dose of 64 g (standard deviation of 25 g; range, 20 to 100g).	62.5% (n=15/24).
Lee <i>et al</i> , JAMA, 2016	Frozen FMT	108	36/72	Mean age 73.0 (+/- 16.4) years.	Unrelated volunteers	Enema	Frozen-100g	90.7% (n=98/109).

	Fresh FMT	111	37/74	Mean age 72.5 (+/- 16.2) years.	Unrelated volunteers	Enema	Fresh-100g	85.6% (n=95/111).
van Nood <i>et al</i> , <i>New England Journal of Medicine</i> , 2013	FMT	16	8/8	Mean 73 (+/- 13) years.	Healthy volunteers	Upper	Fresh A mean (+/- standard deviation) of 141+/-71g of faeces was infused.	94% (n=15/16)
	Vancomycin	13	10/3	69 (+/- 16) years.	N/a	Oral	500mg orally four times daily for 14 days	23% (n=3/13)
Youngster <i>et al</i> , <i>Clinical infectious diseases</i> , 2014	Colonoscopic FMT	10	4/6	Mean 50.4 (+/- 28.8) years.	Healthy volunteers	Colonoscopic	Frozen-90mls of thawed FMT (41g)	100% (n=10/10)
	Nasogastric FMT	10	5/5	Mean 58.6(+/-19.6) years.	Healthy volunteers	Nasogastric	Frozen-90mls of thawed FMT (41g)	80% (n=8/10)

440

441

442

443 **Table 2:** A table outlining published case series of FMT in in *C.diff* infection. Publications that included over 10 patients were included
 444 in the table.

Author	Study level	Demographics			Donors	Route	Fresh/frozen (dose)	Outcome within given follow-up period
		N	M/F	Age				
Aas et al Clinical Infectious Diseases 2003	Case series	18	5/13	73+/-9 (range 53-88)	15 were family members, 3 clinical volunteers.	All Nasogastric	Fresh 30g	15/18 90 days.
Agrawal et al Journal of Clinical Gastroenterology 2016	Case series	146	100/46	78.6 (range 65-97)	Identified by the patient or if not available provided by the physician.	Upper GI 16 lower GI 130	Fresh 60-100g	121/146 (83%) Mean follow up was 12.3 months (range 1-48 months).
Alrabaa et al Transplant Infectious Diseases 2017	Case series	13	5/8	69 (range 59-74)	Unrelated	All Nasoduodenal	Fresh 12.5g	11/13 at eight weeks post-FMT 13/13 at 5 days Follow up up to 8 weeks described.
Brandt et al American Journal of Gastroenterology 2012	Case series	56	21/56	65+/-17 (range 22-87)	45 spouses/ partners 21 relatives 1	All Colonoscopic	Fresh 6 tablespoons	70/77 after one infusion Follow-up period up to 3 years

Chin et al Clinical Gastroenterology & Hepatology 2016	Case series	35	19/16	43 (8 - 93)		5 via nasogastric 3 colonoscopy	Frozen 41g of stool on average frozen.	Not stated
Cohen et al Israel Medical Association Journal 2016	Case series	22	13/9	71.5 (range 16-92)	13 unrelated, rest related.	Nasoduodenal 10 Colonoscopic 10	Fresh and frozen 60g stool average (35-75g)	16/22 at 2 months 16/22 (5/10 upper (out of 7 analysed), 11/12 for lower GI (out of 11 analysed)) Results reported at 2/12, but followed up to 6/12 (7 in the upper, 5 in the lower followed up to 6 months).
Costello et al Alimentary Pharmacology and Therapeutics 2015	Case series	20	N/A	Median age 69	4 healthy volunteers.	Upper GI 1 Lower GI 19	Frozen not stated	17/20 (85%) Minimum 3 months (but up to 14 months).
Dubberke et al Clinical Infectious Diseases 2016	Prospective case series	34	11/23	Median 66.8 (range 26.7-89.6)	4 unrelated donors.	All enema	Frozen 50g	27(87.1%) after 8 week 16(51.6%) of those that received a second infusion 11/14(78%) were considered a success 6 month follow up in 31 patients on safety.

Emanuelsson et al Scandinavian Journal of Infectious Diseases 2014	Case series	23	9/14	Mean 66 years	Donors were spouses or close relative.	All lower GI 23	Fresh 50g	15/23 (65%) Median follow up of 18 months (range 0-201 months).
Fischer et al Inflammatory Bowel Diseases 2016	Case series	67	28/39	mean age 45.42+/ - 17.33	Patient directed donor or unrelated healthy volunteer. months	All lower GI	Fresh did not specify	60 (90%) within 3 months 53 (79%) average length 10.4 months (range 3-36).
Fischer et al American Journal of Gastroenterology 2016	Case series	328	87/241	Mean age 61.4 +/- 19.3	130 (40%) patient directed donors 198 (60%) universal donors.	Upper GI not specifie d Lower GI 249(76. 9%)	Not specified	1 month 81.4%, 1-3 months 97.3% NS
Fischer et al Gut Microbes 2017	Case series	57	23/34	72 (60- 7925- 99)	Patient selected donor in first 28. Donor 29 from OpenBiome stool bank.	All via colonos copy or sigmoid oscopy.	Fresh Did not specify	91% ($n=52/57$), i.e. 100% severe CDI ($n=19/19$), and 87% ($n=33/38$).
Fischer et al Alimentary Pharmacology and Therapeutics 2015	Case series	29	12/17	Mean overall of 65.2 years+/ -	Either patient selected- donor or universal	All via flexible sigmoid oscopy	Fresh 50- 200g of stool	3/12 - 18/29 in remission 7/10 in severe arm 9/19 in severe/

				-17.9 (25-92 years) mean 60.8 (26-87) in severe 67.6 (60-78) in severe/ complic ated	donor screening in all cases. If patient- directed, same donor used for subsequent FMTs if required. 44 total FMTs administered - patient- selected donor for 16, universal donor for 28.	or colonos copy		complicated arm Up to 3 months f/u.
Garborg et al Scandinavian Journal of Infectious Diseases 2010	Case series	40	19/21	Median 75 (range 53-94) years	Close relatives/ household members.	Upper GI 38 Colono scopy 2	Fresh 50- 100g	33/40 29/ 40 (28 in duodenum, 1 in colon) Up to 80 days.
Girotra et al Digestive Diseases and Sciences 2016	Case series	29	23/6	80.1+/- 6.49 years mean (13 patients 70-79, 14 patients 80-89,	Patient- selected family or friend.	Enteros copy 29	Fresh 450cc - 270cc	29/29 Reported 25.37+/- 12.8 months f/u (range 8-50 months).

				2 patients > 90 years)				
Hagel et al Deutsches Arzteblatt International 2016	Case series	133	47/86	Median 75 IQR 59.5 - 81.5	No donor details	4 OGD, 40 enteroscopy, 19 nasoenteric tube 55 'endoscopic' (no further details) capsule 13 2 combination of jejunal and colonos	Fresh and frozen. No dose details	No diarrhoea 30 days 101/120 no diarrhoea 90 days 72/92. Median follow up 141 days (IQR 50-353 days).

						copic FMT		
Hamilton et al American Journal of Gastroenterology 2012	Case series	43	12/31	59+/-21	6 related, 2 spouse, 2 friend s rest unrelated ultimately 30/33 were universal and 3 were patient selected.	All colonos copy	Frozen 50g	95% within 2 months follow-up 86%% 2 months follow FMT and 3 months in one patient.
Hefazi et al Mayo Clinic Proceedings 2017	Case series	23	10/13	Median 66 years (range 23-88).	Donors fresh stool from family/ friends in 10 patients, frozen stool from standard donors in 13 patients.	All colonos copy	not stated if fresh or frozen. Approximatel y 50g	11/12 of haematological malignancy patients (other patient died), 8/10 solid malignancy patients. 19/22 by primary outcome criteria
Hirsch et al BMC Infectious Diseases 2015	Case series	19	6/13	61 range 26-92	3 unrelated. Working in healthcare ns,	All capsule s.	Frozen 2.3g	13(68%) 90 days primary outcome 90 days secondary 6 weeks after this.

Ianiro et al Clinical Microbiology and Infection 2017	Case series	64	25/39	mean 74	36 unrelated and 28 from related. n	All Lower GI	Not reported	97% at 8 weeks 44/64 (69%) 8 weeks.
Kassam et al Archives of Internal Medicine 2012	Case series	27	14/13	69.4 years (mean)	Two healthy volunteers.	All via retention enema	not stated if fresh or frozen 150g	22/27 (81%) Mean follow-up at 427.3 days after transplant.
Kelly et al Journal of Clinical Gastroenterology 2012	Case series	26	2/24	59 years (mean)	25/26 family members 1 friend. Working in healthcare	All via colonoscopy	Fresh 68 tablespoon	24/26 (92.3%) follow-up mean 10.7 months ranged from 2-30 months.
Kelly et al American Journal of Gastroenterology 2014	Case series	80	38/42	Age (mean/median) (75 adults, 5 children)) adults	not mentioned.	Not reported	Not reported	89% within a minimum of 12 weeks 62(78%) 12 weeks post FMT.

				53 years range (20-88) paediatrics 10.9 (range 6.5–16)				
Khoruts et al Clinical Gastroenterology & Hepatology 2016	Case series	272	83/189	Mean 57.2+/- 19.2 years median 59.0 (range 16-100 years)	As per Hamilton paper.	All via colonoscopy	Frozen 50g	74% (n= 32/43) in IBD patients and 92.2% (n=211/229) in non-IBD patients.
Lagier et al European Journal of Clinical Microbiology and Infectious Diseases 2015	Case series	61	21/40	Mean 84 years (66-101)	Preferentially used healthy family members, also used healthy volunteer students and residents.	All nasogastric	Fresh >30g	Global death rate of 3/16 in early transplant arm (day 20, day 37, day 166), 2/3 treated by tardive transplant (day 28, day 54). None of these patients died with evidence of CDI. 1/3 treated by tardive

								FMT dead at day 31 1/16 treated by early FMT dead at day 31
Lee et al European Journal of Clinical Microbiology and Infectious Diseases 2014	Case series	94	41/53	Mean 71.8 years, range 24-95	Volunteers - no further details.	All via retention enema	Not defined	81 in remission after FMT, 5 in remission after FMT-abx-FMT, 8 non-responders follow-up 6 months
MacConnachie et al QJM 2009	Case series	15	1/14	81.5 median (range 68-95 years)	healthy related volunteers	All via upper GI 18	Fresh 30g or 2cm fresh	15/18 (84%) "resolution 84% 90 days
Mattila et al Gastroenterology 2012	Case series	70 Male 28	28/42	Mean 73 (range 22-90 years)	61 close relatives/ other household members in 9 cases, healthy volunteers.	All via colonos copy	Fresh 20- 30ml	94% ($n=66/70$) (100% ($n=34/34$) of those with non-027, 89% ($n=32/36$) with 027) within 12 weeks

Meighani et al European Journal of Gastroenterology and Hepatology 2016	Case series	201	76/125	66.6+/- 18.3 years	Not defined.	Upper GI nasoga stric (+5 through PEG) (76) Lower GI 45 enema, 75 colon	Not defined	176/201 Each patient for 90 days.
Meighani et al Dig Dis Sci 2017	Case series	201	77/124	Mean 68.79+/ -16.78 years for 181 non- IBD patients mean 46.9+/- 19.97 for the 20 IBD patients	Typically family members, but small number of unrelated universal donors. Amongst IBD cohort - 6 patients had family members as donor, universal donor in other 14.	Upper GI 5 NG (IBD patients only not describ ed re non- IBD patients) (5) Lower GI 13 colonos copy (IBD patients	Not defined	158/181 in non-IBD, 15/20 in IBD 31/181 non-IBD relapse within 90 days 25/180 beyond 90 days, 5/20 IBD relapse within 90 days/ 4/20 beyond 90 days.

						only not described re non-IBD patients) 2 retention enema (IBD patients only not described re non-IBD patients) (15)		
Patel et al Mayo Clinic Proceedings 2013	Case series	31	14/17	Mean 61.26+/ 19.34 years	Healthy family/ contacts of recipients - 14 spouses, 9 children, 5 siblings, 3 parents, 1 niece, 1 friend..	All Colono scopy	Fresh 115g (range 18- 397g)	21/23 said diarrhoea no longer present at 1 year, 6/6 reported maintained improvement or resolution 3 months

Pathak et al Clinical & Experimental Gastroenterology 2013	Case series	12	4/8	Mean 71.9 range 37 - 90 years	Preferably family/ first degree relatives family used in all cases here.	Nasodu odenal tube 1 colonos copy 11	Fresh About 6-8 tablespoons f	91.7% ($n=11/12$). Total follow up period 2-26 months.
Rohlke et al Journal of Clinical Gastroenterology 2010	Case series	19	2/17	Mean 49	4 family, 14 partner, 1 housemate	All given via colonos copy	Fresh 350mls	20/20(100%) 19/20(95) 6 months to 5 years
Rubin et al Anaerobe 2013	Case series	75	26/49	63 median (6-94 range)	Healthy close household member of patient.	All upper GI	30g fresh	59/75 (79%) Up to 60 days.
Satokari et al Alimentary Pharmacology and Therapeutics 2015	Case series	49	15/34	Overall with fresh mean 52(22-	15 fresh FMT with individual donor, 11 fresh FMT with universal	All colonos copy	Fresh and frozen Approx 30g	Fresh 96% ($n=25/26$) frozen 96% ($n=22/23$).

				81 range) years frozen 61(20-88 range) years	donor, 23 frozen FMT with universal donor.			Total follow up period 12 weeks.
Yoon et al Journal of Clinical Gastroenterology 2010	Case series	12	3/9	66 years (range 30 - 86 years)	Spouses/ partners as 8/12 one son, two daughters, one granddaughter	All lower GI	Fresh weight unclear. approx 250-450cc of FMT administered in total. Fresh	12/12 (with f/u ranging from 3/52 to 8 years)
Youngster et al JAMA 2014	Prospective case series	20 1	11/9	Median age 64.5 yrs	Unrelated adult volunteers	All capsules	Fresh 48g	18/20 (90%) 14/20 (70%) 8 weeks.
Youngster et al BMC Medicine 2016	Case series	180	Not known	7-95 years (median 64)	Healthy volunteer donor	All capsules	Fresh 41g	91% at 8 weeks 147/190 (82%)% 8 weeks

Zainah et al Digestive Diseases and Sciences 2014	Case series	14	5/9	73.4+/- 11.9 years	Donor was family member, or unrelated if family members not available. 12 FMT from related donor (7 spouse, 5 children) rest unrelated.	Nasoga stric adminis tration in all but one who had colonos copic delivery	Fresh 30- 50g	11/ 14 by seven days 10/ 14 Up to 100 days.
------------------------------------------------------------	----------------	----	-----	--------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------	------------------	---------------------------------------------------

445

446

447

448

449

450

451

452

453

454

455

456

457 **Table 3:** A table outlining published randomised controlled trials of FMT in diseases beyond CDI.

458

Author	Study type	Demographics			Donors	Route of FMT/amount of stool vs comparator	Fresh/frozen (dose)	Outcome within given follow-up period/ cure within one infusion (total follow-up period)
		N	M/F	Age				
Moayyedi <i>et al.</i> <i>Gastroenterology</i> 2015	RCT	Intervention	Intervention	Intervention	unrelated volunteers	Intervention	Fresh and frozen 8.3g	FMT arm Remission rates 24% ($n=9/38$) Clinical response rates 40% ($n=15/38$) had reduction in full Mayo score of at least 3 points. Water enema arm Remission rates 5% ($n=2/37$) ($p=0.03$) Clinical response rates 24% ($n=9/37$) had reduction in full Mayo score of at least 3 points ($p=0.16$).
		38	18/20	42.2+/-15.0 years.		FMT, all via 2 retention enema.		
		Comparator	Comparator	Comparator		Comparator – water enema given via enema		
		37	26/11	35.8 +/- 12.1 years.				

Rossen <i>et al. Gastroenterology</i> 2015	RCT	Intervention 23	Intervention 12/11	Intervention 40 (33-56) years.	Healthy partners, relatives, or volunteers.	Intervention Donor FMT All nasogastric	Not stated if fresh or frozen 120g	Donor faeces arm Remission rates 30% (n=7/23) Clinical response rates 47.8% (n=11/23) at 12 weeks.
		Comparator 25	Comparator 11/41	Comparator 41 (30 – 48) years.		Comparator Autologous FMT All nasogastric		Autologous faeces arm Remission rates 20% (n=5/25), (p=0.51). Clinical response
Paramsothy <i>et al. Lancet</i> 2017	RCT	Intervention 41	Intervention 22/119	Intervention 35.6 (27.8-48.9) years.	3-7 unrelated donors.	Intervention Donor FMT (pooled) All lower GI 5 enemas per week following colonoscopic delivery -5 days on, two days off for 8 weeks (40 enemas per patient)	Frozen 37.5g	Donor FMT arm Remission rates 27% (n=11/41). Clinical response rates 54% (n=22/41).
		Comparator 40	Comparator 25/15	Comparator 35.4 (27.7-45.6) years.		Comparator Isotonic saline		Placebo arm Remission rates 8% (n=3/40) (p=0.021). Clinical response rates 23% (n=9/40) (p=0.04).

						With added colourant and orourant and glycerol cyroprotectant		
Costello <i>et al.</i> <i>Journal of Crohn's and Colitis</i> (abstract) 2017	RCT	Intervention 38 Control 35	Intervention Not stated Control Not stated	Intervention Not stated Control Not stated	Healthy volunteers	Intervention Donor FMT (pooled) All lower GI FMT via colonoscopy on day 0, followed by 2 enemas on day 7 (38) capsule nil Comparator Autologous FMT	Frozen 50g of stool for first FMT, 25g of stool in subsequent enemas.	Donor FMT arm Remission rates 32% (<i>n</i> =12/38) in steroid-free remission at week 8. Clinical response rates 55% (<i>n</i> =21/38). Autologous FMT arm Remission rates 9%. (<i>n</i> =3/35) in steroid-free remission at week 8 (<i>p</i> <0.01). Clinical response rates 20% (<i>n</i> =7/35) (<i>p</i> <0.01).

Johnsen et al <i>Lancet Gastroenterology and Hepatology</i> 2017	RCT	Intervention 55 Control 28	Intervention 119/36 Control 9/19	Intervention 44 (33-54) years. Control 45 (34-57) years	Two volunteers screened at start and at 7 months post donation.	Intervention Donor FMT Comparator Autologous FMT All colonoscopy	Frozen 50 to 80g	Donor FMT arm Remission rates 66% (n=36/55) Autologous FMT arm Remission rates 43% (n=12/28) (p=0.49).
------------------------------------------------------------------------	-----	-----------------------------------------	-----------------------------------------------	----------------------------------------------------------------------	-----------------------------------------------------------------	--------------------------------------------------------------------------------------	------------------	---------------------------------------------------------------------------------------------------------------------------

459
460
461
462
463
464
465
466
467
468
469
470
471
472
473

474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501

References

1. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res.* 2012 Oct;160(4):246–57.
2. Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, Chinwalla AT, et al. Structure, function and diversity of the healthy human microbiome. *Nature.* 2012 Jun 13;486(7402):207–14.
3. Hofer U. Viral evolution: Variation in the gut virome. *Nat Rev Microbiol.* 2013 Jul 22;11(9):596–7.
4. Sokol H, Leducq V, Aschard H, Pham H-P, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. *Gut.* BMJ Publishing Group; 2017 Jun 1;66(6):1039–48.
5. Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. *Virulence.* Taylor & Francis; 2017;8(3):352–8.
6. McIlroy J, Ianiro G, Mukhopadhyaya I, Hansen R, Hold GL. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. *Aliment Pharmacol Ther.* Wiley/Blackwell (10.1111); 2018 Jan 1;47(1):26–42.
7. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med. BioMed Central;* 2016 Dec 27;8(1):51.
8. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature.* 2011 May 12;473(7346):174–80.
9. Marchesi JR, Adams DH, Fava F, Hermes GDA, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. *Gut.* 2016 Feb;65(2):330–9.
10. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of *C. difficile* infection. *American Journal of Gastroenterology.* L.J. Brandt, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, United States. E-mail: lbrandt@montefiore.org; Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom); 2013. p. 177–85.

- 502 11. Bull MJ, Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. *Integr Med (Encinitas)*. InnoVision Media; 2014
503 Dec;13(6):17–22.
- 504 12. Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. *BMJ*. 2017 Mar 15;356:j831.
- 505 13. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal Infusion of Donor Feces for Recurrent
506 *Clostridium difficile*. *N Engl J Med*. Massachusetts Medical Society ; 2013 Jan 31;368(5):407–15.
- 507 14. Faecal microbiota transplant for recurrent *Clostridium difficile* infection | Guidance and guidelines | NICE. NICE;
- 508 15. Hall ic, O’toole e. Intestinal flora in new-born infants. *Am j dis child*. American medical association; 1935 feb 1;49(2):390.
- 509 16. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of *Clostridium difficile* Infection in the United States.
510 *N Engl J Med*. 2015 Feb 26;372(9):825–34.
- 511 17. Pepin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S, et al. Emergence of Fluoroquinolones as the Predominant Risk
512 Factor for *Clostridium difficile*-Associated Diarrhea: A Cohort Study during an Epidemic in Quebec. *Clin Infect Dis*. 2005 Nov
513 1;41(9):1254–60.
- 514 18. Britton RA, Young VB. Role of the Intestinal Microbiota in Resistance to Colonization by *Clostridium difficile*. *Gastroenterology*. 2014
515 May;146(6):1547–53.
- 516 19. Rea MC, Sit CS, Clayton E, O’Connor PM, Whittall RM, Zheng J, et al. Thuricin CD, a posttranslationally modified bacteriocin with a
517 narrow spectrum of activity against *Clostridium difficile*. *Proc Natl Acad Sci*. 2010 May 18;107(20):9352–7.
- 518 20. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, et al. Microbiota transplantation restores normal fecal bile acid composition
519 in recurrent *Clostridium difficile* infection. *AJP Gastrointest Liver Physiol*. 2014 Feb 15;306(4):G310–9.
- 520 21. Sorg JA, Sonenshein AL. Bile Salts and Glycine as Cogerminants for *Clostridium difficile* Spores. *J Bacteriol*. 2008 Apr 1;190(7):2505–
521 12.
- 522 22. Heinlen L, Ballard JD. *Clostridium difficile* Infection. *Am J Med Sci*. 2010 Sep;340(3):247–52.
- 523 23. Leffler DA, Lamont JT. Treatment of *Clostridium difficile*-Associated Disease. *Gastroenterology*. 2009 May;136(6):1899–912.
- 524 24. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. *Clostridium difficile* infection. *Nat Rev Dis Prim*. 2016;2(PG-1-20):1–20.
- 525 25. Lee Y, Lim WI, Bloom CI, Moore S, Chung E, Marzella N. Bezlotoxumab (Zinplava) for *Clostridium Difficile* Infection: The First
526 Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. *P T*. 2017 Dec;42(12):735–8.
- 527 26. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for Prevention of Recurrent *Clostridium difficile*
528 Infection. *N Engl J Med*. Massachusetts Medical Society; 2017 Jan;376(4):305–17.
- 529 27. Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, et al. *Clostridium difficile* Ribotype 027: Relationship to Age, Detectability
530 of Toxins A or B in Stool With Rapid Testing, Severe Infection, and Mortality. *Clin Infect Dis*. Oxford University Press; 2015 Jul
531 15;61(2):233–41.
- 532 28. Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: the efficacy of faecal
533 microbiota transplantation for the treatment of recurrent and refractory *Clostridium difficile* infection. *Aliment Pharmacol Ther*. 2017

- 534 Sep;46(5):479–93.
- 535 29. Hocquart M, Lagier J-C, Cassir N, Saidani N, Eldin C, Kerbaj J, et al. Early Fecal Microbiota Transplantation Improves Survival in
536 Severe *Clostridium difficile* Infections. *Clin Infect Dis An Off Publ Infect Dis Soc Am*. 2018;66(5):645–50.
- 537 30. Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for
538 recurrent *Clostridium difficile* infection. *BMC Med*. 2016 Dec 9;14(1):134.
- 539 31. Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota
540 Transplantation on Recurrent *Clostridium difficile* Infection. *JAMA*. American Medical Association; 2017 Nov 28;318(20):1985.
- 541 32. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota
542 transplantation in clinical practice. *Gut*. BMJ Publishing Group Ltd and British Society of Gastroenterology; 2017 Jan 13;gutjnl-2016-
543 313017.
- 544 33. Hoffmann D, Palumbo F, Ravel J, Roghmann M-C, Rowthorn V, von Rosenvinge E. Improving regulation of microbiota transplants.
545 *Science*. American Association for the Advancement of Science; 2017 Dec 15;358(6369):1390–1.
- 546 34. Ding NS, Mullish BH, McLaughlin J, Hart A, Marchesi JR. Meeting update: faecal microbiota transplantation—bench, bedside,
547 courtroom? *Frontline Gastroenterol*. British Medical Journal Publishing Group; 2016 Nov;flgastro-2016-100752.
- 548 35. Hoffmann DE, Palumbo FB, Ravel J, Rowthorn V, von Rosenvinge E. A proposed definition of microbiota transplantation for regulatory
549 purposes. *Gut Microbes*. 2017 May 4;8(3):208–13.
- 550 36. Megerlin F, Fouassier E. Le transfert de microbiote intestinal à finalité thérapeutique : quel droit applicable en France ? *Ann Pharm*
551 *Françaises*. 2014 Sep;72(5):363–74.
- 552 37. Terveer EM, van Beurden YH, Goorhuis A, Seegers JFML, Bauer MP, van Nood E, et al. How to: Establish and run a stool bank. *Clin*
553 *Microbiol Infect*. 2017 Dec;23(12):924–30.
- 554 38. Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. *J Law Biosci*. 2015;2(2 PG-
555 396-415):396–415.
- 556 39. Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL. A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis
557 B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during
558 2005 to 2010. *Transfusion*. Wiley/Blackwell (10.1111); 2013 Jun 1;53(6):1250–6.
- 559 40. Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM. Establishing a Fecal Microbiota Transplant Service for the Treatment
560 of *Clostridium difficile* Infection. Goldstein EJC, editor. *Clin Infect Dis*. Oxford University Press; 2016 Apr 1;62(7):908–14.
- 561 41. Costello S, La Brooy J, Tucker E, Holloway R, Schoeman M, Andrews JM. Establishment of a fecal microbiota transplant service for the
562 treatment of recurrent *Clostridium difficile* colitis in the Australian public hospital setting. *J Gastroenterol Hepatol*. 2014;29(PG-134):134.
- 563 42. Woodworth MH, Neish EM, Miller NS, Dhere T, Burd EM, Carpentieri C, et al. Laboratory Testing of Donors and Stool Samples for
564 Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection. McAdam AJ, editor. *J Clin Microbiol*. 2017
565 Apr;55(4):1002–10.

- 566 43. OpenBiome [Internet]. [cited 2017 Sep 20]. Available from: <http://www.openbiome.org/>
- 567 44. Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota
568 transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet*. 2017 Mar;389(10075):1218–28.
- 569 45. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent *Clostridium difficile*
570 infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. *Aliment Pharmacol Ther*.
571 2015;42(8):1011–8.
- 572 46. Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazarán S, Martínez-Meléndez A, Palau-Davila L, et al.
573 Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial *Clostridium difficile* infection in intestinal
574 microbiome. Green J, editor. *PLoS One*. Public Library of Science; 2017 Dec 20;12(12):e0189768.
- 575 47. Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, et al. Oral Vancomycin Followed by Fecal Transplantation Versus
576 Tapering Oral Vancomycin Treatment for Recurrent *Clostridium difficile* Infection: An Open-Label, Randomized Controlled Trial. *Clin*
577 *Infect Dis*. R Foundation for Statistical Computing, Vienna, Austria; 2017 Feb 1;64(3):265–71.
- 578 48. Randomized Trial Colleen Kelly AR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of Fecal Microbiota
579 Transplantation on Recurrence in Multiply Recurrent *Clostridium difficile* Infection.
- 580 49. Cammarota G, Masucci L, Ianiro G, Bibbò S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation
581 by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment Pharmacol Ther*. 2015
582 May;41(9):835–43.
- 583 50. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing *Clostridium difficile*
584 infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. *Clin Infect Dis*. Oxford
585 University Press; 2014 Jun;58(11):1515–22.
- 586 51. König J, Siebenhaar A, Högenauer C, Arkkila P, Nieuwdorp M, Norén T, et al. Consensus report: faecal microbiota transfer - clinical
587 applications and procedures. *Aliment Pharmacol Ther*. 2017 Jan;45(2):222–39.
- 588 52. Ianiro G, Valerio L, Masucci L, Pecere S, Bibbò S, Quaranta G, et al. Predictors of failure after single faecal microbiota transplantation in
589 patients with recurrent *Clostridium difficile* infection: results from a 3-year, single-centre cohort study. *Clin Microbiol Infect*. 2017
590 May;23(5):337.e1-337.e3.
- 591 53. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in
592 Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology*. 2015 Jul;149(1):102–109.e6.
- 593 54. Kapel N, Thomas M, Corcos O, Mayeur C, Barbot-Trystram L, Bouhnik Y, et al. Practical implementation of faecal transplantation. *Clin*
594 *Microbiol Infect*. 2014;20(11 PG-1098-1105):1098–105.
- 595 55. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, et al. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical
596 Resolution of Diarrhea in Patients With Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *JAMA*. 2016;315(2 PG-
597 142-9):142–9.

- 598 56. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev. American Society for Microbiology (ASM);
599 2005 Jan;18(1):195–204.
- 600 57. Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the
601 Elderly: Long-Term Outcomes and Microbiota Changes. Dig Dis Sci. 2016 Oct 22;61(10):3007–15.
- 602 58. Hagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A, et al. Fecal Microbiota Transplant in Patients With Recurrent
603 Clostridium Difficile Infection. Dtsch Arztebl Int. 2016 Sep 5;113(35–36):583–9.
- 604 59. Aas J, Gessert CE, Bakken JS. Recurrent *Clostridium difficile* Colitis: Case Series Involving 18 Patients Treated with Donor Stool
605 Administered via a Nasogastric Tube. Clin Infect Dis. Oxford University Press; 2003 Mar 1;36(5):580–5.
- 606 60. Alrabaa S, Jariwala R, Zeitler K, Montero J. Fecal microbiota transplantation outcomes in immunocompetent and immunocompromised
607 patients: A single-center experience. Transpl Infect Dis. 2017 Aug 1;19(4):e12726.
- 608 61. Cohen NA, Livovsky DM, Yaakovovitch S, Ben Yehoyada M, Ben Ami R, Adler A, et al. A Retrospective Comparison of Fecal
609 Microbial Transplantation Methods for Recurrent Clostridium Difficile Infection. Isr Med Assoc J. 2016 Oct;18(10):594–9.
- 610 62. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent Clostridium difficile infection: Report on a case
611 series. Anaerobe. 2013 Feb;19:22–6.
- 612 63. Zainah H, Hassan M, Shiekh-Sroujeh L, Hassan S, Alangaden G, Ramesh M. Intestinal Microbiota Transplantation, a Simple and
613 Effective Treatment for Severe and Refractory Clostridium Difficile Infection. Dig Dis Sci. 2015 Jan 23;60(1):181–5.
- 614 64. Cohen NA, Livovsky DM, Yaakovovitch S, Ben Yehoyada M, Ben Ami R, Adler A, et al. fecal microbiota transplantation (FMT),
615 Clostridium difficile, diarrhea, bacteriotherapy, colonoscopy, gastroscopy a retrospective Comparison of Fecal Microbial Transplantation
616 Methods for recurrent Clostridium difficile Infection. IMAJ. 2016;18:594–9.
- 617 65. Jiang ZD, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, et al. Randomised clinical trial: faecal microbiota transplantation for
618 recurrent *Clostridium difficile* infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by
619 colonoscopy. Aliment Pharmacol Ther. 2017 Apr 1;45(7):899–908.
- 620 66. Patel NC, Griesbach CL, DiBaise JK, Orenstein R. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Mayo Clinic
621 in Arizona Experience. Mayo Clin Proc. 2013 Aug;88(8):799–805.
- 622 67. Furuya-Kanamori L, Doi SAR, Paterson DL, Helms SK, Yakob L, McKenzie SJ, et al. Upper Versus Lower Gastrointestinal Delivery for
623 Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection: A Collaborative Analysis of Individual
624 Patient Data From 14 Studies. J Clin Gastroenterol. 2016;11(PG-).
- 625 68. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal Microbiota Transplantation for Clostridium difficile Infection: Systematic Review and
626 Meta-Analysis. Am J Gastroenterol. 2013 Apr 19;108(4):500–8.
- 627 69. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016 Feb;92(2):117–27.
- 628 70. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized Frozen Preparation for Transplantation of Fecal Microbiota for
629 Recurrent Clostridium difficile Infection. Am J Gastroenterol. 2012 May 31;107(5):761–7.

- 630 71. Ray A, Smith R, Breaux J. Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience. *Ochsner J.*
631 2014;14(4):538–44.
- 632 72. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal Microbiota Transplant for Treatment of Clostridium
633 difficile Infection in Immunocompromised Patients. *Am J Gastroenterol.* 2014 Jul;109(7):1065–71.
- 634 73. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. *Clin Infect Dis.*
635 2015;61(1 PG-136-137):136–7.
- 636 74. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up
637 of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. *United Eur Gastroenterol J.*
638 SAGE Publications; 2017 Oct;5(6):868–79.
- 639 75. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal
640 microbiota transplantation: Systematic review and meta-analysis. *Gut Microbes.* Taylor & Francis; 2017 Jul;1–15.
- 641 76. Schwartz M, Gluck M, Koon S. Norovirus Gastroenteritis After Fecal Microbiota Transplantation for Treatment of Clostridium difficile
642 Infection Despite Asymptomatic Donors and Lack of Sick Contacts. *Am J Gastroenterol.* 2013 Aug;108(8):1367–1367.
- 643 77. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant
644 for recurrent Clostridium difficile infection. *Am J Gastroenterol.* 2012;107(7):1079–87.
- 645 78. Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, et al. The Long-term Efficacy and Safety of Fecal Microbiota
646 Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. *J Clin Gastroenterol.* 2015
647 Aug;50(5):1.
- 648 79. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. *Open forum Infect Dis.* Oxford University Press; 2015
649 Jan;2(1):ofv004.
- 650 80. Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, et al. Stool Donor Body Mass Index Does Not Affect Recipient Weight After a
651 Single Fecal Microbiota Transplantation for C. difficile Infection. *Clin Gastroenterol Hepatol.* W.B. Saunders; 2017 Dec;
- 652 81. Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, et al. Faecal Microbiota Transplantation for
653 Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *J Crohn's Colitis.* Vienna; 2017 May 9;22(5 Suppl):2402–9.
- 654 82. Johnsen PH, Hilpüsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for
655 moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. *Lancet*
656 *Gastroenterol Hepatol.* 2018 Jan;3(1):17–24.
- 657 83. Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial.
- 658 84. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al. Transfer of Intestinal Microbiota From Lean
659 Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. *Gastroenterology.* 2012 Oct;143(4):913–916.e7.
- 660 85. Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, et al. Fecal microbiota transplant from a rational stool donor improves hepatic
661 encephalopathy: A randomized clinical trial. *Hepatology.* 2017;66(6):1727–38.

- 662 86. Davido B, Salomon J, Lawrence C, Duran C, Batista R, de Truchis P, et al. Impact of Fecal Microbiota Transplantation for
663 Decolonization of Multidrug-Resistant Organisms May Vary According to Donor Microbiota. *Clin Infect Dis*. Oxford University Press;
664 2017 Dec 19;66(8):1316–7.
- 665 87. Manges AR, Steiner TS, Wright AJ. Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-
666 resistant opportunistic pathogens: a review. *Infect Dis (Auckl)*. 2016 Aug 2;48(8):587–92.
- 667 88. Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D. Faecal microbiota transplantation for stool decolonization of OXA-48
668 carbapenemase-producing *Klebsiella pneumoniae*. *Journal of Hospital Infection*. 2015. p. 173–4.
- 669 89. Petrof EO, Claud EC, Gloor GB, Allen-Vercoe E. Microbial ecosystems therapeutics: a new paradigm in medicine? *Benef Microbes*.
670 2013 Mar 1;4(1):53–65.
- 671
- 672
- 673
- 674
- 675
- 676
- 677
- 678
- 679
- 680
- 681
- 682
- 683
- 684
- 685